Submission of newspaper publication for financial results for the quarter and year ended March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories has submitted newspaper copies of its audited financial results for Q4 FY26 and full year ended March 31, 2026, published in Financial Express, Jansatta, and Business Standard on June 1, 2026. On a standalone basis, total income from operations rose sharply to Rs. 15,560.53 lakhs for the full year (vs Rs. 6,423.10 lakhs in FY25), with profit after tax of Rs. 811.55 lakhs (vs Rs. 892.53 lakhs). On a consolidated basis, total income from operations grew to Rs. 21,160.05 lakhs (vs Rs. 16,036.33 lakhs), and net profit after tax jumped to Rs. 2,744.72 lakhs (vs Rs. 1,827.01 lakhs). The Board approved the results on May 30, 2026, recommended a dividend of Rs. 0.50 per share, and noted the equity share subdivision (from Rs. 10 to Rs. 2 face value) effective February 20, 2026.
The filing is a routine regulatory disclosure under SEBI LODR Regulation 47, but it confirms strong year-on-year topline growth at the consolidated level and a healthy PAT, alongside a maiden dividend declaration and a 1:5 stock split — likely positive signals for retail shareholders regarding liquidity and shareholder returns.